Featured products

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC20052	CB-6644 Featured	CB-6644 is a selective inhibitor of RUVBL1/2 complex with anti-cancer activity. CB-6644 blocks the ATPase activity of RUVBL1/2 with an IC50 of 15 nM.
DC10449	CB7921220 Featured	CB7921220 is an inhibitor of Adenylyl Cyclase isoform-1 (AC1) and isoform-6 (AC6).
DC8042	CB-839(Telaglenastat) Featured	CB-839 is a potent, selective, reversible and orally bioavailable inhibitor of human glutaminase.
DC10617	CBL0137 Featured	CBL0137 is a metabolically stable curaxin that activates p53 with an EC50 value of 0.37 µM and inhibits NF-κB with an EC50 of 0.47 µM.
DC8377	CC-115 Featured	CC-115 is a dual inhibitor of DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR), with potential antineoplastic activity.
DC10146	Avadomide（CC 122） Featured	Avadomide is an orally bioavailable cereblon modulator that regulates cereblon E3 ligase activity, inhibits the NF-κB pathway, and induces cell cycle arrest at the G1 phase, leading to apoptosis in pancreatic ductal adenocarcinoma (PDAC) cells. It demonstrates significant antitumor and immunomodulatory effects.
DC8497	CC-223 Featured	CC-223 is a potent mTOR kinase inhibitor (IC50=16 nM), with >150-fold sensitivity over the related lipid kinase PI3Kα (IC50=4 μM).
DC7096	CC-401 Featured	CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.
DC20866	CC-671 Featured	CC-671 is a potent, selective, dual TTK (Mps1)/CLK2 inhibitor with IC50 of 5/3 nM, respectively.
DC11588	CC-885 Featured	CC-885 (CC 885, CC885) is a novel modulator of the E3 ligase cereblon (CRBN) that exhibits strong anti-tumor activity by promoting the degradation of the protein GSPT1.
DC12590	CCB 02 Featured	CCB02 (CCB 02) is a specific small molecule inhibitor of CPAP-tubulin interaction with IC50 of 0.689 uM in AlphaScreen assay, selectively binds at the CPAP binding site of tubulin.
DC7319	CCDC(TGR5-Receptor-Agonist) Featured	CCDC is a otent, selective TGR5 G-protein coupled receptor agonist (pEC50 = 6.8).
DC9757	CCF642 Featured	CCF642 is a novel protein disulfide isomerases (PDI) inhibitor.
DC7979	CCG1423 Featured	CCG-1423 is a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis.
DC10535	CCG-203971 Featured	CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50 = 6.4 μM), with 87% inhibition of SRE activation achieved at 100 μM.
DC11302	CCG215022 Featured	CCG215022 is a G protein-coupled receptor kinases (GRKs) inhibitor with IC50s of 0.15±0.07 μM, 0.38±0.06 μM and 3.9±1 μM for GRK2, GRK5 and GRK1, respectively.
DC22819	CCG-50014 Featured	CCG-50014 is the most potent against the regulator of G-protein signaling protein type 4 (RGS4) (IC50 =30 nM) and is >20-fold selective for RGS4 over other RGS proteins. CCG-50014 binds covalently to the RGS, forming an adduct on two cysteine residues located in an allosteric regulatory site. CCG50014, reduces nociceptive responses and enhances opioid-mediated analgesic effects in the mouse formalin test.
DC26030	CCMI Featured	CCMI is a positive allosteric modulator of α7 neuronal nicotinic acetylcholine receptors (nAChR).
DC12302	CCR2 antagonist 3 Featured	CCR2 antagonist 3 is a chemokine receptor 2 (CCR2) antagonist.
DC7803	CCT007093 Featured	CCT007093 is a potent PPM1D (WIP1) inhibitor with IC50 of 8.4 μM.
DC23163	CCT129202 Featured	CCT129202 is a potent, selective, ATP-competitive pan-Aurora kinase inhibitor with IC50 of 42, 198 and 227 nM for Aurora A, Aurora B and Aurora C, respectively.
DC10005	CCT196969 Featured	CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity.
DC10911	CCT241736 Featured	CCT241736 is a novel, orally bioavailable Dual FLT3-Aurora Kinase Inhibitor.
DC8324	CCT244747 Featured	CCT244747 represents the first structural disclosure of a highly selective, orally active CHK1 inhibitor and warrants further evaluation alone or combined with genotoxic anticancer therapies.
DC10498	CCT251236 Featured	CCT251236 is an orally available pirin ligand from a heat shock transcription factor 1 (hsf1) phenotypic screen with an IC50 of 19 nM for inhibition of HSF1-mediated HSP72 induction.
DC9968	CCT251545 Featured	CCT251545 is an orally bioavailable and potent inhibitor of WNT signaling with IC50 value of 5 nM.
DC11679	CCT-367766 Featured	CCT367766 is a potent and the third generation heterobifunctional and PROTAC-based pirin targeting protein degradation probe (PDP), depletes pirin protein expression at low concentration. CCT367766 exhibits a moderate affinity for the CRBN-DDB1 complex with an IC50 value of 490 nM. CCT367766 reveals a good affinity for the recombinant pirin and CRBN with Kd values of 55 nM and 120 nM, respectively. CCT367766 provides a potential chemical tool to study a largely unexplored protein[1].
DC20332	CD38 inhibitor 78c Featured	CD38 inhibitor 78c is a potent, specific, reversible CD38 inhibitor with Ki of 14.5 nM for recombinant human CD38.
DC10491	CD437 Featured	CD437 is a synthetic retinoid that is an RARγ-selective agonist. It displays RARγ-dependent and -independent effects on differentiation and apoptosis.
DC10909	BN82002 Featured	CDC25 Phosphatase Inhibitor I, BN82002, is a cell-permeable ortho-hydroxybenzylamino compound that has been reported to display antitumor properties.

Featured products

Customized Consultation X

Your information is safe with us. * Required Fields.